Light-Activated Carbon Monoxide Prodrugs Based on Bipyridyl Dicarbonyl Ruthenium(II) Complexes

Chemistry. 2020 Aug 26;26(48):10992-11006. doi: 10.1002/chem.202002139. Epub 2020 Aug 13.

Abstract

Two photoactivatable dicarbonyl ruthenium(II) complexes based on an amide-functionalised bipyridine scaffold (4-position) equipped with an alkyne functionality or a green-fluorescent BODIPY (boron-dipyrromethene) dye have been prepared and used to investigate their light-induced decarbonylation. UV/Vis, FTIR and 13 C NMR spectroscopies as well as gas chromatography and multivariate curve resolution alternating least-squares analysis (MCR-ALS) were used to elucidate the mechanism of the decarbonylation process. Release of the first CO molecule occurs very quickly, while release of the second CO molecule proceeds more slowly. In vitro studies using two cell lines A431 (human squamous carcinoma) and HEK293 (human embryonic kidney cells) have been carried out in order to characterise the anti-proliferative and anti-apoptotic activities. The BODIPY-labelled compound allows for monitoring the cellular uptake, showing fast internalisation kinetics and accumulation at the endoplasmic reticulum and mitochondria.

Keywords: anti-apoptotic activity; anti-proliferative; cellular localisation; photoCORM; ruthenium(II).

MeSH terms

  • 2,2'-Dipyridyl / chemistry*
  • Carbon Monoxide / chemistry*
  • Cell Line, Tumor
  • HEK293 Cells
  • Humans
  • Prodrugs / chemistry*
  • Prodrugs / radiation effects*
  • Ruthenium / chemistry*

Substances

  • Prodrugs
  • 2,2'-Dipyridyl
  • Carbon Monoxide
  • Ruthenium